Dr. Michael Postow, MD – New York, NY

Overview of Dr. Postow

Dr. Michael Postow is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from New York University Grossman School of Medicine and has been in practice 12 years. He is one of 468 doctors at Memorial Sloan-Kettering Cancer Center and one of 83 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

Certifications & Licensure

• FL State Medical License 2021 - Present

• NJ State Medical License 2019 - 2025

• NY State Medical License 2010 - 2025

• CT State Medical License 2023 - 2024

• MA State Medical License 2009 - 2012

• American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

• Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis.

  Sala, I., Pagan, E., Pala, L., Oriecuia, C., Musca, M., Specchia, C., De Pas, T., Cortes, J., Gelber, R., Bagnardi, V., Conforti, F., Giaccone, G., Postow, M.> ;Frontiers in Immunology. 2024 Jan 1

• Recent Advances in the Field of Artificial Intelligence for Precision Medicine in Patients with a Diagnosis of Metastatic Cutaneous Melanoma.

  Hayley Higgins, Abanoub Nakhla, Andrew Lotfalla, David Khalil, Parth Doshi, Vandan Thakkar, Dorsa Shirini, Maria Bebawy, Samy Ammari, Egesta Lopci, Lawrence H Schwartz...> ;Diagnostics. 2023 Nov 20

• Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.

  Paul B Chapman, Mark Klang, Michael A Postow, Ryan J Sullivan, Taha Merghoub, Sadna Budhu, Phillip Wong, Margaret K Callahan, Bin Zheng, Shoushtari, A., Zippin, J., Wo...> ;Cancer Research Communications. 2023 Dec 4
• Join now to see all

Journal Articles

• Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain  

  Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine

• Marked Response of a Hypermutated Adrenocorticotropic Hormone-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab  

  Michael Postow, Viviane Tabar, T Jonathan Yang, John Cuaron, Jinru Shia, Lisa M DeAngelis, The Journal of Clinical Endocrinology and Metabolism

• Melanoma Brain Metastases Treated with Stereotactic Radiosurgery and Concurrent Pembrolizumab Display Marked Regression; Efficacy and Safety of Combined Treatment  

  Jedd D Wolchok, Kathryn Beal, Yoshiya Yamada, Michael A Postow, BioMed Central

Lectures

• Treatment of Advanced Melanoma After Progression on PD-1 Blockade 

  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

• Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiotherapy (RT) in patients with metastatic melanoma. 

  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

• Melanoma and Other Skin Cancers. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 1) 

  2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

• Timing of Melanoma Immunotherapy Could Be Key to Outcomes: StudyMarch 6th, 2023

• Melanoma Research Alliance Announces $8.1 Million in Research AwardsApril 27th, 2021

• How Should We Evaluate the Benefit of Immunotherapy Combinations?December 10th, 2020

• Join now to see all

Hospital Affiliations